A Cell Line-based Neutralization Assay for Primary Human Immunodeficiency Virus Type 1 Isolates That Use Either the CCR5 or the CXCR4 Coreceptor

Overview

Journal J Virol

Publisher American Society for Microbiology

Date 1999 Oct 9

PMID 10516002

Citations 127

Authors

A Trkola

J Matthews

C Gordon

T Ketas

J P Moore

Affiliations

Soon will be listed here.

Abstract

We describe here a cell line-based assay for the evaluation of human immunodeficiency virus type 1 (HIV-1) neutralization. The assay is based on CEM.NKR cells, transfected to express the HIV-1 coreceptor CCR5 to supplement the endogenous expression of CD4 and the CXCR4 coreceptor. The resulting CEM.NKR-CCR5 cells efficiently replicate primary HIV-1 isolates of both R5 and X4 phenotypes. A comparison of the CEM.NKR-CCR5 cells with mitogen-activated peripheral blood mononuclear cells (PBMC) in neutralization assays with sera from HIV-1-infected individuals or specific anti-HIV-1 monoclonal antibodies shows that the sensitivity of HIV-1 neutralization is similar in the two cell types. The CEM.NKR-CCR5 cell assay, however, is more convenient to perform and eliminates the donor-to-donor variation in HIV-1 replication efficiency, which is one of the principal drawbacks of the PBMC-based neutralization assay. We suggest that this new assay is suitable for the general measurement of HIV-1 neutralization by antibodies.

Citing Articles

NK cell depletion in bispecific antibody therapy is associated with lack of HIV control after ART interruption.

Sanchez-Gaona N, Perea D, Curran A, Burgos J, Navarro J, Suanzes P Commun Biol. 2025; 8(1):236.

PMID: 39953264 PMC: 11829058. DOI: 10.1038/s42003-025-07651-6.

Increased Chemokine Production is a Hallmark of Rhesus Macaque Natural Killer Cells Mediating Robust Anti-HIV Envelope-Specific Antibody-Dependent Cell-Mediated Cytotoxicity.

Nohara J, Evangelous T, Berry M, Beck W, Mudrak S, Jha S Pathog Immun. 2025; 10(1):49-79.

PMID: 39911143 PMC: 11792536. DOI: 10.20411/pai.v10i1.734.

NK Count and Natural Cytotoxicity in Immune Nonresponders Versus Responders Living With HIV.

Silvestre C, Tuaillon E, Duroyon M, Abrantes M, Thibout J, Villalba M J Med Virol. 2025; 97(2):e70170.

PMID: 39868926 PMC: 11771562. DOI: 10.1002/jmv.70170.

Downregulation of miRNA-26a by HIV-1 Enhances CD59 Expression and Packaging, Impacting Virus Susceptibility to Antibody-Dependent Complement-Mediated Lysis.

Bellini N, Ye C, Ajibola O, Murooka T, Lodge R, Cohen E Viruses. 2024; 16(7).

PMID: 39066239 PMC: 11281366. DOI: 10.3390/v16071076.

Multivariate analysis of FcR-mediated NK cell functions identifies unique clustering among humans and rhesus macaques.

Tuyishime M, Spreng R, Hueber B, Nohara J, Goodman D, Chan C Front Immunol. 2023; 14:1260377.

PMID: 38124734 PMC: 10732150. DOI: 10.3389/fimmu.2023.1260377.

References

Lee B, Sharron M, Montaner L, Weissman D, Doms R . Quantification of CD4, CCR5, and CXCR4 levels on lymphocyte subsets, dendritic cells, and differentially conditioned monocyte-derived macrophages. Proc Natl Acad Sci U S A. 1999; 96(9):5215-20. PMC: 21844. DOI: 10.1073/pnas.96.9.5215. View

Poignard P, Sabbe R, Picchio G, Wang M, Gulizia R, Katinger H . Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo. Immunity. 1999; 10(4):431-8. DOI: 10.1016/s1074-7613(00)80043-6. View

Montefiori D, Evans T . Toward an HIV type 1 vaccine that generates potent, broadly cross-reactive neutralizing antibodies. AIDS Res Hum Retroviruses. 1999; 15(8):689-98. DOI: 10.1089/088922299310773. View

Ortiz G, Nixon D, Trkola A, Binley J, Jin X, Bonhoeffer S . HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy. J Clin Invest. 1999; 104(6):R13-8. PMC: 408442. DOI: 10.1172/JCI7371. View

Doranz B, Grovit-Ferbas K, Sharron M, Mao S, Goetz M, Daar E . A small-molecule inhibitor directed against the chemokine receptor CXCR4 prevents its use as an HIV-1 coreceptor. J Exp Med. 1997; 186(8):1395-400. PMC: 2199097. DOI: 10.1084/jem.186.8.1395. View

Gauduin M, Parren P, Weir R, Barbas C, Burton D, Koup R . Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1. Nat Med. 1997; 3(12):1389-93. DOI: 10.1038/nm1297-1389. View

Trkola A, Paxton W, Monard S, Hoxie J, Siani M, Thompson D . Genetic subtype-independent inhibition of human immunodeficiency virus type 1 replication by CC and CXC chemokines. J Virol. 1998; 72(1):396-404. PMC: 109387. DOI: 10.1128/JVI.72.1.396-404.1998. View

Donzella G, Schols D, Lin S, Este J, Nagashima K, Maddon P . AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nat Med. 1998; 4(1):72-7. DOI: 10.1038/nm0198-072. View

Parren P, Moore J, Burton D, Sattentau Q . The neutralizing antibody response to HIV-1: viral evasion and escape from humoral immunity. AIDS. 2000; 13 Suppl A:S137-62. View

10.

Toyoshima K, Vogt P . Enhancement and inhibition of avian sarcoma viruses by polycations and polyanions. Virology. 1969; 38(3):414-26. DOI: 10.1016/0042-6822(69)90154-8. View

11.

Gervaix A, West D, Leoni L, Richman D, Wong-Staal F, Corbeil J . A new reporter cell line to monitor HIV infection and drug susceptibility in vitro. Proc Natl Acad Sci U S A. 1997; 94(9):4653-8. PMC: 20779. DOI: 10.1073/pnas.94.9.4653. View

12.

Wu L, Paxton W, Kassam N, Ruffing N, Rottman J, Sullivan N . CCR5 levels and expression pattern correlate with infectability by macrophage-tropic HIV-1, in vitro. J Exp Med. 1997; 185(9):1681-91. PMC: 2196298. DOI: 10.1084/jem.185.9.1681. View

13.

Vodicka M, Goh W, Wu L, Rogel M, Bartz S, Schweickart V . Indicator cell lines for detection of primary strains of human and simian immunodeficiency viruses. Virology. 1997; 233(1):193-8. DOI: 10.1006/viro.1997.8606. View

14.

Deng H, Unutmaz D, Kewalramani V, Littman D . Expression cloning of new receptors used by simian and human immunodeficiency viruses. Nature. 1997; 388(6639):296-300. DOI: 10.1038/40894. View

15.

Sullivan N, Sun Y, Li J, Hofmann W, Sodroski J . Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates. J Virol. 1995; 69(7):4413-22. PMC: 189183. DOI: 10.1128/JVI.69.7.4413-4422.1995. View

16.

Trkola A, Pomales A, Yuan H, Korber B, Maddon P, Allaway G . Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG. J Virol. 1995; 69(11):6609-17. PMC: 189569. DOI: 10.1128/JVI.69.11.6609-6617.1995. View

17.

Morgan J, Ledoux J, Snow R, Tompkins R, Yarmush M . Retrovirus infection: effect of time and target cell number. J Virol. 1995; 69(11):6994-7000. PMC: 189618. DOI: 10.1128/JVI.69.11.6994-7000.1995. View

18.

Allaway G, Beaudry G, Garcia E, Wong E, Ryder A, Hasel K . Expression and characterization of CD4-IgG2, a novel heterotetramer that neutralizes primary HIV type 1 isolates. AIDS Res Hum Retroviruses. 1995; 11(5):533-9. DOI: 10.1089/aid.1995.11.533. View

19.

Haynes B, Pantaleo G, Fauci A . Toward an understanding of the correlates of protective immunity to HIV infection. Science. 1996; 271(5247):324-8. DOI: 10.1126/science.271.5247.324. View

20.

Vancott T, Polonis V, Loomis L, Michael N, Nara P, Birx D . Differential role of V3-specific antibodies in neutralization assays involving primary and laboratory-adapted isolates of HIV type 1. AIDS Res Hum Retroviruses. 1995; 11(11):1379-91. DOI: 10.1089/aid.1995.11.1379. View